Last reviewed · How we verify
(+)-Ketoprofen (DEXKETOPROFEN)
DEXKETOPROFEN, also known as (+)-Ketoprofen, is a small molecule drug class of dexketoprofen that targets Prostaglandin G/H synthase 1. It is used to treat various conditions, although its specific approved indications are unknown. The commercial status of DEXKETOPROFEN is also unclear, with information on its patent status, generic manufacturers, and off-patent status not available. As a result, its availability and safety considerations cannot be fully assessed. Further research is needed to understand the full scope of DEXKETOPROFEN.
At a glance
| Generic name | DEXKETOPROFEN |
|---|---|
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Target | Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1994 |
Approved indications
Boxed warnings
- Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS ). • Ketoprofen extended-release capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS ). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal (GI) events (see WARNINGS ).
Common side effects
- Acute kidney injury
- Tubulointerstitial nephritis
- Hepatic cytolysis
- Angioedema
- Polyneuropathy in malignant disease
- Hyperbilirubinaemia
- Hypocoagulable state
- Hyperaesthesia
- Drug interaction
- Quality of life decreased
- Anaphylactic reaction
- Allodynia
Key clinical trials
- Ear Pressure Points Plus Pain Meds for Faster Kidney Stone Pain Relief (NA)
- Postoperative Analgesic Efficacy of SPSIPB in Anterior Cervical Discectomy (NA)
- Comparison of the Postoperative Analgesic Effects of SPSIPB and TPB in Mastectomy Operations (NA)
- Comparing the Safety and Effectiveness of Different Doses of Morphine Administered in Spinal Anethesia for Pain Relief After Hip Replacement Surgery (PHASE4)
- Intrathecal Morphine for Recovery and Outcomes After VATS (NA)
- Short-term Perfusion Effects: Dexketoprofen/Tramadol (NA)
- Comparison of the Postoperative Analgesic Efficacy of SPSIPB and ISBPB (NA)
- Perioperative Effects of Lateral Quadratus Lumborum Block in Percutaneous Transhepatic Cholangiography (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (+)-Ketoprofen CI brief — competitive landscape report
- (+)-Ketoprofen updates RSS · CI watch RSS